Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Needle Therapy for Major Depressive Disorder
NCT05352113Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Zhejiang Chinese Medical University
- Start
- May 2022
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) (3 arms), sponsored by Third Affiliated Hospital of Zhejiang Chinese Medical University. Primary endpoint: Hamilton Depression Scale-17 at 10 weeks. Planned start May 2022; status: not yet recruiting.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05352113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352113.